title: Namibia becomes first country in Africa to launch dabigatran etexilate for atrial fibrillation.
authors: P
authors: P
authors: Wagenaar
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000069604:Dabigatran; D017277:Drug Approval; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009276:Namibia; D018579:Patient Selection; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran